科研之友
微信
新浪微博
Facebook
分享链接
摘要
The clinical value of antiplatelet compounds strongly depends on the 1 benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.
- 出版日期2013-11
